Erul Enes, Uzun Gullu Sandal, Koksal Deniz, Keskin Onur, Uysal Serkan, Inkaya Ahmet Cagkan, Kalyoncu Umut
Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Eur J Case Rep Intern Med. 2022 Aug 25;9(8):003515. doi: 10.12890/2022_003515. eCollection 2022.
Behçet's disease (BD) is multisystemic vasculitis with heterogeneous clinical manifestations. We describe the case of a 26-year-old man who presented with Budd-Chiari syndrome (BCS) related to BD. The patient received infliximab (IFX) due to the severity of vascular involvement. Subsequently, after IFX therapy, hospital-acquired pneumonia, trapped lung, and fungal infection of the lung and central nervous system developed as complications. The patient benefited from a second course of IFX and clinical remission was achieved following early identification and treatment of complications. Data on the presentation and prognosis of BCS related to BD are extremely limited. Our case report supports the growing evidence that anti-TNF antibody is a promising treatment for BD-related BCS.
Behçet's disease-related Budd-Chiari syndrome is a rare form of vascular involvement that severely affects mortality.Behçet's disease-related Budd-Chiari syndrome is frequently confused with idiopathic thrombosis and may be underdiagnosed.Infliximab could be a therapeutic option for refractory Behçet's disease with major vascular involvement, but the increased risk of opportunistic infections should be kept in mind.
白塞病(BD)是一种具有异质性临床表现的多系统血管炎。我们描述了一名26岁男性患者,其出现了与白塞病相关的布加综合征(BCS)。由于血管受累严重,该患者接受了英夫利昔单抗(IFX)治疗。随后,在IFX治疗后,出现了医院获得性肺炎、肺陷闭以及肺部和中枢神经系统真菌感染等并发症。患者受益于第二疗程的IFX治疗,并且在并发症得到早期识别和治疗后实现了临床缓解。与白塞病相关的BCS的表现和预后数据极为有限。我们的病例报告支持了越来越多的证据,即抗TNF抗体是治疗与白塞病相关的BCS的一种有前景的疗法。
白塞病相关的布加综合征是一种罕见的血管受累形式,严重影响死亡率。白塞病相关的布加综合征常与特发性血栓形成相混淆,可能未得到充分诊断。英夫利昔单抗可能是治疗伴有主要血管受累的难治性白塞病的一种治疗选择,但应牢记机会性感染风险增加。